Opportunity Information: Apply for CDC RFA GH21 2135
This CDC funding opportunity (CDC RFA GH21-2135) is a PEPFAR-supported cooperative agreement focused on expanding and strengthening comprehensive HIV prevention, care, and treatment services in Tanzania, with a specific emphasis on people living with HIV (PLHIV) and populations at higher risk and with greater barriers to services, including key and vulnerable populations (KVP) and adolescent girls and young women (AGYW). The overall intent is to accelerate Tanzania's progress toward the UNAIDS 95-95-95 targets by improving the full HIV service continuum: finding people with HIV who do not yet know their status, rapidly linking those individuals to treatment, keeping them engaged in long-term care, supporting strong treatment adherence, and ultimately achieving and sustaining viral suppression.
Funding is expected to be substantial at the program level, even though the notice lists an award ceiling of $0 for Year 1 (meaning no fixed maximum per individual award is specified in the announcement). CDC anticipated approximately $35,000,000 in total funding for the first fiscal year, contingent on availability of funds, and expected to make around two awards. Because this is a cooperative agreement, recipients should expect an active partnership with CDC, typically involving substantial CDC involvement in planning, technical guidance, monitoring, evaluation, and performance improvement as the work proceeds.
Programmatically, the opportunity emphasizes "advanced differentiated service delivery" (DSD), meaning service models should be tailored to the needs and circumstances of different groups rather than relying on a single, uniform approach. In practical terms, this includes designing convenient and effective pathways for prevention and treatment that reflect differences in age, risk profile, mobility, stigma and discrimination challenges, and the varying points at which people may drop off the care continuum. The approach prioritizes comprehensive HIV prevention services alongside treatment scale-up, recognizing that prevention, testing, and care engagement need to be coordinated if case identification and viral suppression targets are to be met.
A central feature of the work is scaling up innovative and targeted HIV case-finding strategies. The notice highlights index testing (testing services offered to partners and contacts of people diagnosed with HIV), HIV self-testing (HIVST) to expand reach and privacy, and risk screening approaches to better target who should be tested and when. The goal is not only to increase testing volume, but to improve yield and ensure testing reaches those most likely to be undiagnosed, especially within KVP and AGYW groups. Once individuals test positive, the program expects strong systems for linkage to care and long-term retention, so that diagnosis leads quickly to initiation of antiretroviral therapy (ART) and sustained treatment.
The opportunity also stresses integrated, comprehensive service delivery rather than siloed programming. Recipients are expected to support models that incorporate or closely connect HIV services with pre-exposure prophylaxis (PrEP) for HIV-negative people at substantial risk, TB/HIV services given the overlapping burden and clinical interaction, prevention of mother-to-child transmission (PMTCT) to protect infants and support pregnant and breastfeeding women, and access to medication-assisted therapy (MAT) for people with opioid use disorder, where relevant, as part of a broader approach to reaching vulnerable groups and improving outcomes. This integration reflects the reality that many clients need multiple services at once and are more likely to stay engaged when care is coordinated and accessible.
Geographically, the initial focus is on high-burden regions: Mwanza, Kagera, Geita, and Dar es Salaam. However, the announcement makes it clear that geographic focus could shift over time based on performance, epidemiological data, changes in where CDC supports activities, and changes in where key populations are concentrated or which KVP subgroups are prioritized. This signals an expectation that recipients will be able to adapt operations and resource deployment in response to data and program results, rather than assuming a fixed footprint for the full project period.
Finally, recipients may be funded to conduct community-based activities, facility-based activities, or a combination of both, depending on the region and the award structure. Community activities typically address demand creation, outreach, peer navigation, stigma reduction, self-testing distribution, and linkage support, while facility activities often focus on clinical service delivery, quality improvement, ART initiation and follow-up, viral load monitoring and suppression, and integration with TB, PMTCT, and PrEP services. The flexibility to award by setting and region indicates CDC is looking for implementers that can deliver measurable improvements across the prevention-to-treatment cascade, with a strong focus on populations and places where gaps are largest and the potential impact is highest.
Key administrative details included in the notice are that it was issued by the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention (CDC), Center for Global Health (CGH), under CFDA 93.067 as a discretionary cooperative agreement. Eligibility was listed as unrestricted (open to any entity type, subject to any additional eligibility clarifications in the full announcement). The opportunity was originally posted on January 13, 2021, with an original application deadline of March 14, 2021 (electronic submissions due by 11:59 p.m. ET).Apply for CDC RFA GH21 2135
- The Department of Health and Human Services, Centers for Disease Control - CGH in the health sector is offering a public funding opportunity titled "Scaling Up Comprehensive Facility and Community HIV Prevention, Care and Treatment Programs for Key and Vulnerable Populations, and People Living with HIV (PLHIV) in Tanzania under the President's Emergency Plan for AIDS Relief (PEPFAR)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.067.
- This funding opportunity was created on Jan 13, 2021.
- Applicants must submit their applications by Mar 14, 2021 Electronically submitted applications must be submitted no later than 1159 p.m., ET, on the listed application due date.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The number of recipients for this funding is limited to 2 candidate(s).
- Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is CDC RFA GH21-2135?
CDC RFA GH21-2135 is a PEPFAR-supported CDC cooperative agreement focused on expanding and strengthening comprehensive HIV prevention, care, and treatment services in Tanzania. The opportunity is designed to improve outcomes across the full HIV service continuum, from identifying people living with HIV who do not yet know their status through sustained viral suppression.
What is the main goal of this funding opportunity?
The main goal is to accelerate Tanzania's progress toward the UNAIDS 95-95-95 targets by strengthening the full continuum of HIV services: finding undiagnosed people with HIV, rapidly linking them to treatment, keeping them engaged in long-term care, supporting adherence, and achieving and sustaining viral suppression.
Which populations are emphasized in this program?
The opportunity specifically emphasizes people living with HIV (PLHIV) and populations at higher risk and with greater barriers to services. This includes key and vulnerable populations (KVP) and adolescent girls and young women (AGYW).
What does it mean that this award is a cooperative agreement?
Because this is a cooperative agreement, recipients should expect an active partnership with CDC, including substantial CDC involvement in planning, technical guidance, monitoring, evaluation, and performance improvement during implementation.
How much funding is expected for this opportunity?
CDC anticipated approximately $35,000,000 in total funding for the first fiscal year, contingent on availability of funds.
How many awards did CDC expect to make?
CDC expected to make around two awards.
Why does the notice list an award ceiling of $0 for Year 1?
The listing of an award ceiling of $0 for Year 1 indicates that no fixed maximum per individual award is specified in the announcement, even though the overall program-level funding was expected to be substantial.
What is the geographic focus of activities in Tanzania?
The initial focus is on high-burden regions: Mwanza, Kagera, Geita, and Dar es Salaam.
Can the geographic focus change during the project?
Yes. The announcement states that geographic focus could shift over time based on performance, epidemiological data, changes in where CDC supports activities, and changes in where key populations are concentrated or which KVP subgroups are prioritized.
What is meant by "advanced differentiated service delivery" (DSD)?
Advanced differentiated service delivery (DSD) means tailoring HIV prevention and treatment service models to the needs and circumstances of different groups rather than using a single uniform approach. The intent is to design convenient and effective pathways that reflect differences in age, risk profile, mobility, stigma and discrimination barriers, and where people are likely to drop off along the care continuum.
Does the opportunity focus only on treatment, or also on prevention?
It emphasizes both. The opportunity prioritizes comprehensive HIV prevention services alongside treatment scale-up, recognizing that prevention, testing, and care engagement need to be coordinated to meet case identification and viral suppression targets.
What HIV testing and case-finding strategies are highlighted?
The notice highlights index testing (testing services offered to partners and contacts of people diagnosed with HIV), HIV self-testing (HIVST), and risk screening approaches to better target who should be tested and when.
Is the goal to increase the number of tests, or to improve testing results?
The goal is not only to increase testing volume, but also to improve yield and ensure testing reaches people most likely to be undiagnosed, especially within KVP and AGYW groups.
What happens after someone tests HIV-positive under this program?
The program expects strong systems for linkage to care and long-term retention so that diagnosis leads quickly to initiation of antiretroviral therapy (ART) and sustained treatment.
What does "linkage to care" and "retention" mean in the context of this opportunity?
In this opportunity, linkage to care refers to connecting individuals who test HIV-positive to HIV treatment services quickly. Retention refers to keeping clients engaged in long-term care over time, including adherence support and follow-up to achieve and sustain viral suppression.
What is meant by "integrated, comprehensive service delivery"?
Integrated service delivery means programs should avoid siloed programming and instead incorporate or closely connect HIV services with other related services. The intent is to coordinate care so clients can access multiple services more easily and remain engaged in care.
Which services are expected to be integrated with HIV programming?
The opportunity references integration with or close connection to PrEP (for HIV-negative people at substantial risk), TB/HIV services, prevention of mother-to-child transmission (PMTCT), and access to medication-assisted therapy (MAT) for people with opioid use disorder, where relevant.
Does the opportunity include PrEP?
Yes. The notice states recipients are expected to support models that incorporate or closely connect HIV services with pre-exposure prophylaxis (PrEP) for HIV-negative people at substantial risk.
How does TB/HIV integration fit into this program?
The opportunity emphasizes TB/HIV services given the overlapping burden and clinical interaction, indicating that HIV programming should be connected to TB-related services as part of comprehensive service delivery.
How does PMTCT fit into this program?
PMTCT is highlighted as an expected integration area to protect infants and support pregnant and breastfeeding women through coordinated HIV-related services.
Is medication-assisted therapy (MAT) part of the expected approach?
Yes, the notice references access to medication-assisted therapy (MAT) for people with opioid use disorder, where relevant, as part of reaching vulnerable groups and improving outcomes.
Are activities expected to be community-based, facility-based, or both?
Recipients may be funded to conduct community-based activities, facility-based activities, or a combination of both, depending on the region and the award structure.
What are examples of community-based activities described in the notice?
Community activities typically include demand creation, outreach, peer navigation, stigma reduction, self-testing distribution, and linkage support.
What are examples of facility-based activities described in the notice?
Facility activities often focus on clinical service delivery, quality improvement, ART initiation and follow-up, viral load monitoring and suppression, and integration with TB, PMTCT, and PrEP services.
Is the program expected to be data-driven and adaptive?
Yes. The announcement signals an expectation that recipients can adapt operations and resource deployment based on performance, epidemiological data, program results, and changes in CDC-supported activities or key population concentrations.
Which U.S. agency issued this funding opportunity?
The notice was issued by the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention (CDC), Center for Global Health (CGH).
What is the CFDA number for this opportunity?
The opportunity is listed under CFDA 93.067.
What type of funding mechanism is this?
It is described as a discretionary cooperative agreement.
Who is eligible to apply?
Eligibility was listed as unrestricted (open to any entity type), subject to any additional eligibility clarifications in the full announcement.
When was the opportunity originally posted?
The opportunity was originally posted on January 13, 2021.
What was the original application deadline?
The original application deadline was March 14, 2021, with electronic submissions due by 11:59 p.m. ET.
Browse more opportunities from the same category: Health
Next opportunity: Office of Career, Technical, and Adult Education (OCTAE): Native Hawaiian Career and Technical Education Program (NHCTEP), Assistance Listing Number 84.259A
Previous opportunity: DRL FY2020: Supporting Human Rights Defenders in Libya
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CDC RFA GH21 2135
Applicants also applied for:
Applicants who have applied for this opportunity (CDC RFA GH21 2135) also looked into and applied for these:
| Funding Opportunity |
|---|
| Advancing Arthritis Public Health Priorities through National Organizations Apply for CDC RFA DP21 2106 Funding Number: CDC RFA DP21 2106 Agency: Department of Health and Human Services, Centers for Disease Control - NCCDPHP Category: Health Funding Amount: $1,000,000 |
| Vision Screening in Young Children Program Apply for HRSA 21 033 Funding Number: HRSA 21 033 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: $300,000 |
| HIV/TB Agency, Information, and Services Activity (HIV/TB AIS) Apply for 72048221RFA00001 Funding Number: 72048221RFA00001 Agency: Agency for International Development, Burma USAID - Rangoon Category: Health Funding Amount: $39,000,000 |
| USAID Improved Family Planning Initiative Apply for 72065621RFA00001 IFPI Funding Number: 72065621RFA00001 IFPI Agency: Agency for International Development, Mozambique USAID-Maputo Category: Health Funding Amount: $39,900,011 |
| Autism Field-Initiated Innovative Research Studies Program (Autism-FIRST) Apply for HRSA 21 053 Funding Number: HRSA 21 053 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| SPOTLIGHT: A Social Medicine, HIV Provider Stigma and Bias Prevention Project Apply for 72052121RFA00001 Funding Number: 72052121RFA00001 Agency: Agency for International Development, Haiti USAID-Port Au Prince Category: Health Funding Amount: $900,000 |
| Promoting Cancer Surveillance Workforce, Education, and Data Use Apply for CDC RFA DP21 2104 Funding Number: CDC RFA DP21 2104 Agency: Department of Health and Human Services, Centers for Disease Control - NCCDPHP Category: Health Funding Amount: $500,000 |
| Advancing Comprehensive Community-Based HIV Services to Achieve Epidemic Control in Namibia under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH21 2153 Funding Number: CDC RFA GH21 2153 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: Case Dependent |
| Bridging the Word Gap Research Network (BWG) Apply for HRSA 21 040 Funding Number: HRSA 21 040 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Money Follows the Person Rebalancing Demonstration Program - Capacity Building Apply for CMS 1LI 21 001 Funding Number: CMS 1LI 21 001 Agency: Department of Health and Human Services, Centers for Medicare Medicaid Services Category: Health Funding Amount: $5,000,000 |
| NIOSH Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed) Apply for PAR 21 148 Funding Number: PAR 21 148 Agency: Department of Health and Human Services, Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $20,000 |
| Continuation and Expansion of the National Mesothelioma Virtual Bank for Translational Research (U24) Apply for RFA OH 21 007 Funding Number: RFA OH 21 007 Agency: Department of Health and Human Services, Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $1,100,000 |
| The Microbicide 2021 Introduction and Access Project Apply for 7200AA21RFA00008 Funding Number: 7200AA21RFA00008 Agency: Agency for International Development Category: Health Funding Amount: $85,000,000 |
| President's Malaria Initiative Eliminate Malaria (PMI-EM) Activity Apply for 72048221RFA00002 Funding Number: 72048221RFA00002 Agency: Agency for International Development, Burma USAID - Rangoon Category: Health Funding Amount: $30,000,000 |
| Military Health System Research (MHSR) Apply for 22 DHA MHSR Funding Number: 22 DHA MHSR Agency: Department of Defense, Defense Health Agency Category: Health Funding Amount: $10,000,000 |
| Comprehensive Addiction and Recovery Act (CARA) Local Drug Crises Grants Apply for CDC RFA CE21 2103 Funding Number: CDC RFA CE21 2103 Agency: Department of Health and Human Services, Centers for Disease Control - NCIPC Category: Health Funding Amount: $50,000 |
| Service Delivery for HIV Prevention Apply for 72061121RFA00001 Funding Number: 72061121RFA00001 Agency: Agency for International Development, Zambia USAID-Lusaka Category: Health Funding Amount: $75,000,000 |
| Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation’s Health Apply for CDC RFA OT18 18020301SUPP21 Funding Number: CDC RFA OT18 18020301SUPP21 Agency: Department of Health and Human Services, Centers for Disease Control - OSTLTS Category: Health Funding Amount: $250,000 |
| High-End Instrumentation (HEI) Grant Program (S10 Clinical Trial Not Allowed) Apply for PAR 21 126 Funding Number: PAR 21 126 Agency: Department of Health and Human Services, National Institutes of Health Category: Health Funding Amount: $2,000,000 |
| Shared Instrumentation Grant (SIG) Program (S10 Clinical Trial Not Allowed) Apply for PAR 21 127 Funding Number: PAR 21 127 Agency: Department of Health and Human Services, National Institutes of Health Category: Health Funding Amount: $600,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CDC RFA GH21 2135", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.